Creative Medical Technology Holdings Enters Material Agreement

TL;DR

CMED signed a big deal, details TBD.

AI Summary

Creative Medical Technology Holdings, Inc. announced on October 22, 2024, that it entered into a material definitive agreement. The filing does not provide specific details about the agreement, its terms, or any associated dollar amounts. The company is incorporated in Nevada and its principal executive offices are located in Phoenix, Arizona.

Why It Matters

This filing indicates a significant development for Creative Medical Technology Holdings, Inc., suggesting a new contract or partnership that could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.

Key Players & Entities

• Creative Medical Technology Holdings, Inc. (company) — Registrant
• October 22, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• Phoenix, AZ (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share CELZ The Nasdaq Stock Mar
• $4.42 — tock") at a purchase price per share of $4.42. The Company estimates that the net pr
• $1.6 million — gistered Offering will be approximately $1.6 million after deducting certain fees due to the
• $75,000 — -pocket expenses in the amount of up to $75,000, and to issue the Placement Agent, or i

Filing Documents

• celz_8k.htm (8-K) — 32KB
• celz_ex41.htm (EX-4.1) — 111KB
• celz_ex42.htm (EX-4.2) — 93KB
• celz_ex51.htm (EX-5.1) — 11KB
• celz_ex101.htm (EX-10.1) — 230KB
• celz_ex102.htm (EX-10.2) — 93KB
• celz_ex991.htm (EX-99.1) — 10KB
• celz_ex991img2.jpg (GRAPHIC) — 6KB
• celz_ex51img3.jpg (GRAPHIC) — 10KB
• 0001477932-24-006644.txt ( ) — 860KB
• celz-20241022.xsd (EX-101.SCH) — 6KB
• celz-20241022_lab.xml (EX-101.LAB) — 14KB
• celz-20241022_cal.xml (EX-101.CAL) — 1KB
• celz-20241022_pre.xml (EX-101.PRE) — 9KB
• celz-20241022_def.xml (EX-101.DEF) — 2KB
• celz_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 22, 2024, Creative Medical Technology Holdings, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Investors"), pursuant to which the Company agreed to sell and issue in a registered direct offering (the "Registered Offering") 418,552 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock") at a purchase price per share of $4.42. The Company estimates that the net proceeds from the Registered Offering will be approximately $1.6 million after deducting certain fees due to the Placement Agent (as defined below) and the Company's estimated expenses. The net proceeds received by the Company will be used for working capital and general corporate purposes. The Shares are being offered pursuant to the Company's effective registration statement on Form S-3 (File No. 333-282512), which was filed with the Securities and Exchange Commission (the "Commission") on October 4, 2024 and declared effective by the Commission on October 15, 2024 (the "Registration Statement"). Pursuant to the Purchase Agreement, in a concurrent private placement (the "Private Placement" and together with the Registered Offering, the "Offering"), the Company has also agreed to issue to the Investors warrants to purchase up to 837,104 shares of Common Stock at an exercise price of $4.42 per share (the "Warrants"). The Warrants will not be exercisable until the Company has obtained stockholder approval for the issuance of the shares of Common Stock underlying the Warrants as required by the applicable rules and regulations of the Nasdaq Stock Market, including Nasdaq Listing Rule 5635(d), and will then be exercisable for a period of five years following the date the Company obtains such stockholder approval. The Purchase Agreement contains customary representations, warranties and agreements of the Company

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Pachulski Stang Ziehl & Jones LLP 10.1 Securities Purchase Agreement dated October 22, 2024 between Creative Medical Technology Holdings, Inc. and the Purchasers party thereto 10.2 Placement Agency Agreement dated October 22, 2024 between Creative Medical Technology Holdings, Inc. and Roth Capital Partners 23.1 Consent of Pachulski Stang Ziehl & Jones LLP (included in Exhibit 5.1) 99.1 Press Release dated October 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Creative Medical Technology Holdings, Inc. Date: October 23, 2024 By: /s/ Timothy Warbington Timothy Warbington, Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR